GLS and cancer: Overexpression of MYCN in non-MYCN-amplified NB cells sensitized treatment with the GLS inhibitor L-6-diazo-5-oxo-L-norleucine (L-DON).93 Thus, c-MYC as well as MYCN have been described to induce glutamine addiction in cancer cells, with enhanced glutaminolysis and a crucial role in cancer cell survival.